LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer.

@inproceedings{Patnaik2014LY2835219AN,
  title={LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer.},
  author={Amita Patnaik and Lee S. Rosen and Sara M. Tolaney and Anthony William Tolcher and Jonathan Wade Goldman and Leena Gandhi and Kyriakos P Papadopoulos and Muralidhar Beeram and Drew Warren Rasco and Scott P. Myrand and Palaniappan Kulanthaivel and Joan M. Andrews and Martin Frenzel and Damien M. Cronier and Edward Michael Chan and Keith T Flaherty and Patrick Y.C. Wen and Geoffrey I. Shapiro},
  year={2014}
}

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Similar Papers

Loading similar papers…